44|10000|Public
2500|$|Capp, <b>Al,</b> <b>et</b> al. Famous Artists Cartoon Course— 3 volumes (1956) Famous Artists School ...|$|E
5000|$|In {{lists of}} places, et alibi may be used, {{which is also}} {{abbreviated}} et <b>al.</b> <b>et</b> alibi means [...] "and elsewhere".|$|E
5000|$|Bayne, Rosemary <b>AL,</b> <b>et</b> al. [...] "Molecular Profiling of the Human Testis Reveals Stringent Pathway‐Specific Regulation of RNA Expression Following Gonadotropin Suppression and Progestogen Treatment." [...] Journal of andrology29.4 (2008): 389-403.|$|E
30|$|Several {{major issues}} {{were found for}} both knee-to-knee and knee-to-ankle mosaicplasty procedure. The type of study was poorly scored and {{included}} small sample sizes (n[*]<[*] 20) (Reddy <b>et</b> <b>al.</b> 2007; Al-Shaikh <b>et</b> <b>al.</b> 2002; Atik <b>et</b> <b>al.</b> 2005; Gautier <b>et</b> <b>al.</b> 2002; Kock <b>et</b> <b>al.</b> 2010; Koulalis <b>et</b> <b>al.</b> 2004; Lee <b>et</b> <b>al.</b> 2003; Quarch <b>et</b> <b>al.</b> 2014; Reverte-Vinaixa <b>et</b> <b>al.</b> 2013; Valderrabano <b>et</b> <b>al.</b> 2009). In addition, the procedure for assessing the outcomes (Reddy <b>et</b> <b>al.</b> 2007; Al-Shaikh <b>et</b> <b>al.</b> 2002; Atik <b>et</b> <b>al.</b> 2005; Baltzer & Arnold 2005; de l'Escalopier <b>et</b> <b>al.</b> 2015; Gautier <b>et</b> <b>al.</b> 2002; Hangody <b>et</b> <b>al.</b> 2001 a; Hangody <b>et</b> <b>al.</b> 2008; Jakob <b>et</b> <b>al.</b> 2002; Kim <b>et</b> <b>al.</b> 2012; Koulalis <b>et</b> <b>al.</b> 2004; Lee <b>et</b> <b>al.</b> 2003; Quarch <b>et</b> <b>al.</b> 2014) and {{the description of the}} subject selection process (Hangody <b>et</b> <b>al.</b> 2010; Espregueira-Mendes <b>et</b> <b>al.</b> 2012; Reddy <b>et</b> <b>al.</b> 2007; Ahmad & Jones 2015; Al-Shaikh <b>et</b> <b>al.</b> 2002; Atik <b>et</b> <b>al.</b> 2005; Baltzer & Arnold 2005; de l'Escalopier <b>et</b> <b>al.</b> 2015; Gautier <b>et</b> <b>al.</b> 2002; Hangody <b>et</b> <b>al.</b> 2001 a; Hangody <b>et</b> <b>al.</b> 2008; Jakob <b>et</b> <b>al.</b> 2002; Kim <b>et</b> <b>al.</b> 2012; Kock <b>et</b> <b>al.</b> 2010; Koulalis <b>et</b> <b>al.</b> 2004; Lee <b>et</b> <b>al.</b> 2003; Quarch <b>et</b> <b>al.</b> 2014; Reverte-Vinaixa <b>et</b> <b>al.</b> 2013; Valderrabano <b>et</b> <b>al.</b> 2009; Kreuz <b>et</b> <b>al.</b> 2006) were also poorly reported across the included original studies.|$|R
30|$|Other {{themes were}} less well-represented by checklists: 13 checklists (52 %) {{contained}} no items on “Team working”(Lee <b>et</b> <b>al.</b> 2009; Lobo <b>et</b> <b>al.</b> 2005; Millington <b>et</b> <b>al.</b> 2009; Murphy <b>et</b> <b>al.</b> 2008; Rosen <b>et</b> <b>al.</b> 2009; Ramakrishna <b>et</b> <b>al.</b> 2005; Blaivas and Adhikari 2009; Carvalho 2007; Stone <b>et</b> <b>al.</b> 2010; Kilbourne <b>et</b> <b>al.</b> 2009; Coopersmith <b>et</b> <b>al.</b> 2002; Xiao <b>et</b> <b>al.</b> 2007; Yilmaz <b>et</b> <b>al.</b> 2007); 14 checklists (56 %) contained no items on “Communication {{and working with}} the patient” (Berenholtz <b>et</b> <b>al.</b> 2004; Blaivas and Adhikari 2009; Britt <b>et</b> <b>al.</b> 2009; Carvalho 2007; Coopersmith <b>et</b> <b>al.</b> 2002; Kilbourne <b>et</b> <b>al.</b> 2009; Lobo <b>et</b> <b>al.</b> 2005; McKee <b>et</b> <b>al.</b> 2008; Millington <b>et</b> <b>al.</b> 2009; Papadimos <b>et</b> <b>al.</b> 2008; Stone <b>et</b> <b>al.</b> 2010; Velmahos <b>et</b> <b>al.</b> 2004; Xiao <b>et</b> <b>al.</b> 2007; Yilmaz <b>et</b> <b>al.</b> 2007); seven checklists (28 %) contained no items on “Post-procedure” (Ramakrishna <b>et</b> <b>al.</b> 2005; Blaivas and Adhikari 2009; Carvalho 2007; Stone <b>et</b> <b>al.</b> 2010; Kilbourne <b>et</b> <b>al.</b> 2009; Xiao <b>et</b> <b>al.</b> 2007; Yilmaz <b>et</b> <b>al.</b> 2007); seven checklists (28 %) contained no items on “Safety” (Berenholtz <b>et</b> <b>al.</b> 2004; McKee <b>et</b> <b>al.</b> 2008; Millington <b>et</b> <b>al.</b> 2009; Papadimos <b>et</b> <b>al.</b> 2008; Ramakrishna <b>et</b> <b>al.</b> 2005; Xiao <b>et</b> <b>al.</b> 2007; Yilmaz <b>et</b> <b>al.</b> 2007); and six checklists (24 %) contained no items on “Procedural competence” (Coopersmith <b>et</b> <b>al.</b> 2002; Costello <b>et</b> <b>al.</b> 2008; Lobo <b>et</b> <b>al.</b> 2005; McKee <b>et</b> <b>al.</b> 2008; Xiao <b>et</b> <b>al.</b> 2007; Yilmaz <b>et</b> <b>al.</b> 2007).|$|R
30|$|The {{production}} of lignolytic enzymes and its regulation has been intensively studied in various lignin degrading fungi (Bonnarme &Jeffries 1990;Hakala <b>et</b> <b>al.</b> 2006; Jiménez-Tobon <b>et</b> <b>al.</b> 2003;Kamitsuji <b>et</b> <b>al.</b> 2004;Lankinen <b>et</b> <b>al.</b> 2005; Martínez <b>et</b> <b>al.</b> 1996;Moilanen <b>et</b> <b>al.</b> 1996;Nuske <b>et</b> <b>al.</b> 2002; Perie &Gold 1991;Palma <b>et</b> <b>al.</b> 2000;Petruccioli <b>et</b> <b>al.</b> 2009;Schneegab <b>et</b> <b>al.</b> 1997; Swamy &Ramsay 1999;Steffen <b>et</b> <b>al.</b> 2002;Susla <b>et</b> <b>al.</b> 2008;Silva <b>et</b> <b>al.</b> 2008;Sklenar <b>et</b> <b>al.</b> 2010;Singh <b>et</b> <b>al.</b> 2011; Taboada-Puig <b>et</b> <b>al.</b> 2011;Vares <b>et</b> <b>al.</b> 1995;Wang <b>et</b> <b>al.</b> 2001;Wang <b>et</b> <b>al.</b> 2008) and novel bacterial strains (Bharagava <b>et</b> <b>al.</b> 2009; Mishra &Thakur 2010;Yadav <b>et</b> <b>al.</b> 2011). Recombinant production {{has been studied}} in filamentous fungi (Conesa <b>et</b> <b>al.</b> 2000;Irie <b>et</b> <b>al.</b> 2001;Li <b>et</b> <b>al.</b> 2001;Mayfield <b>et</b> <b>al.</b> 1994;Stewart <b>et</b> <b>al.</b> 1996), yeasts (Jiang <b>et</b> <b>al.</b> 2008 a), bacterial (Whitwam &Tien 1996) and insect (Johnson <b>et</b> <b>al.</b> 1992; Pease <b>et</b> <b>al.</b> 1991) hosts with successful production but modest yields of active enzyme. MnP from P. chrysosporium has {{been the target of}} most recombinant studies, which however suffer from unsuccessful posttranslational protein modification and the need for exogenous heme in high concentrations (Jiang <b>et</b> <b>al.</b> 2008 a).|$|R
5000|$|Dans, <b>A.L.</b> <b>et</b> al., 1998. Users’ Guides to the Medical Literature: XIV. How to Decide on the Applicability of Clinical Trial Results to Your Patient. JAMA, 279(7), pp. 545-549. Available at: http://jama.ama-assn.org/cgi/doi/10.1001/jama.279.7.545 ...|$|E
50|$|Hill, D., 1974. An {{introduction}} to the Great Barrier Reef. In : Cameron, <b>A.L.</b> <b>et</b> al. (eds), Proceedings of the 2nd International Symposium on Coral Reefs, vol. 2, The Great Barrier Reef Committee, Brisbane, 723-731.|$|E
5000|$|... #Caption: Guitang Material Flow {{modified}} from Qinghua, Zhu, Ernest Loew, et <b>al.,</b> <b>et</b> al. [...] "Industrial Symbiosis in China: A {{case study}} of the Guitang Group." [...] Journal of Industrial Ecology. 11. (2007): 31-42. Web. 15 Apr. 2013.|$|E
30|$|Recently, genetic {{studies of}} IPMN lead to {{discover}} mutations of new genes, including GNAS, and RNF 43 (Macgregor-Das and Iacobuzio-Donahue 2013; Reid <b>et</b> <b>al.</b> 2014). In {{addition to the}} previously known genetic alteration such as KRAS, these gene mutations open a new viewpoint {{in the field of}} the molecular pathogenesis of IPMN. Nevertheless, the frequencies and clinicopathologic significances of KRAS, GNAS, and RNF 43 have not been clearly delineated. Activating GNAS mutation at codon 201 has been identified in IPMNs of the pancreas, which runs from 36 to 79  % (Amato <b>et</b> <b>al.</b> 2014; Hosoda <b>et</b> <b>al.</b> 2015; Ideno <b>et</b> <b>al.</b> 2015; Kanda <b>et</b> <b>al.</b> 2013; Kuboki <b>et</b> <b>al.</b> 2015; Lee <b>et</b> <b>al.</b> 2014; Siddiqui <b>et</b> <b>al.</b> 2013; Singhi <b>et</b> <b>al.</b> 2014; Takano <b>et</b> <b>al.</b> 2014; Tan <b>et</b> <b>al.</b> 2015; Wu <b>et</b> <b>al.</b> 2011 b). Moreover, the wide extreme diversity of KRAS mutation in IPMN patients, ranged from 13 to 100  %, has been observed (Amato <b>et</b> <b>al.</b> 2014; Chadwick <b>et</b> <b>al.</b> 2009; Chang <b>et</b> <b>al.</b> 2014; Fritz <b>et</b> <b>al.</b> 2009; Furukawa <b>et</b> <b>al.</b> 2005; Hosoda <b>et</b> <b>al.</b> 2015; Ideno <b>et</b> <b>al.</b> 2015; Jang <b>et</b> <b>al.</b> 2009; Kaino <b>et</b> <b>al.</b> 1999; Kitago <b>et</b> <b>al.</b> 2004; Kobayashi <b>et</b> <b>al.</b> 2008; Kondo <b>et</b> <b>al.</b> 1997; Kuboki <b>et</b> <b>al.</b> 2015; Lee <b>et</b> <b>al.</b> 2014; Lubezky <b>et</b> <b>al.</b> 2011; Mizuno <b>et</b> <b>al.</b> 2010; Mohri <b>et</b> <b>al.</b> 2012; Mueller <b>et</b> <b>al.</b> 2003; Mulligan <b>et</b> <b>al.</b> 1999; Nakata <b>et</b> <b>al.</b> 2002; Paal <b>et</b> <b>al.</b> 1999; Raimondo <b>et</b> <b>al.</b> 2002; Schönleben <b>et</b> <b>al.</b> 2008; Sessa <b>et</b> <b>al.</b> 1994; Siddiqui <b>et</b> <b>al.</b> 2013; Singhi <b>et</b> <b>al.</b> 2014; Tada <b>et</b> <b>al.</b> 1991; Takano <b>et</b> <b>al.</b> 2014; Tan <b>et</b> <b>al.</b> 2015; Uemura <b>et</b> <b>al.</b> 2003; Wada <b>et</b> <b>al.</b> 2004; Wu <b>et</b> <b>al.</b> 2011 b; Yoshizawa <b>et</b> <b>al.</b> 2002). The frequency of RNF 43 mutation was ranged from 14 to 75  % (Amato <b>et</b> <b>al.</b> 2014; Sakamoto <b>et</b> <b>al.</b> 2015; Tan <b>et</b> <b>al.</b> 2015; Wu <b>et</b> <b>al.</b> 2011 a).|$|R
30|$|One {{hundred and}} twenty-eight {{articles}} described 350 cases of NOVC bacteraemia involving 347 patients, 3 of whom {{presented with a}} second episode (Additional file 1 : Table S 1) (Petsaris <b>et</b> <b>al.</b> 2010; Mannion and Mellor 1986; Lai <b>et</b> <b>al.</b> 2012; Morris <b>et</b> <b>al.</b> 1981; Anderson <b>et</b> <b>al.</b> 2004; Pierce <b>et</b> <b>al.</b> 2000; Hlady and Klontz 1996; Magnusson and Pegg 1996; Robins-Browne <b>et</b> <b>al.</b> 1977; Eltahawy <b>et</b> <b>al.</b> 2004; Marcenac <b>et</b> <b>al.</b> 1991; Ferreira <b>et</b> <b>al.</b> 2012; Zarate <b>et</b> <b>al.</b> 2011; Goei and Karthigasu 1978; Trubiano <b>et</b> <b>al.</b> 2014; Heath <b>et</b> <b>al.</b> 2001; Guard <b>et</b> <b>al.</b> 1980; Hsu <b>et</b> <b>al.</b> 2013; Huhulescu <b>et</b> <b>al.</b> 2007; Halabi <b>et</b> <b>al.</b> 1997; Berghmans <b>et</b> <b>al.</b> 2002; Kadkhoda <b>et</b> <b>al.</b> 2012; Burns <b>et</b> <b>al.</b> 1989; Ramsingh 1998; Briceno <b>et</b> <b>al.</b> 2009; Young <b>et</b> <b>al.</b> 1991; Lu <b>et</b> <b>al.</b> 2014; Farmachidi <b>et</b> <b>al.</b> 2003; Chong <b>et</b> <b>al.</b> 1985; Choi <b>et</b> <b>al.</b> 2003; Dalsgaard <b>et</b> <b>al.</b> 2000; Marek <b>et</b> <b>al.</b> 2013; Aguinaga <b>et</b> <b>al.</b> 2009; Forné <b>et</b> <b>al.</b> 1987; Prats <b>et</b> <b>al.</b> 1975; Lopez-Brea <b>et</b> <b>al.</b> 1985; Mirelis <b>et</b> <b>al.</b> 1987; Royo <b>et</b> <b>al.</b> 1993; Mauri <b>et</b> <b>al.</b> 1987; Esparcia <b>et</b> <b>al.</b> 2000; Fernández <b>et</b> <b>al.</b> 2000; Lantero <b>et</b> <b>al.</b> 1984; Folgueira <b>et</b> <b>al.</b> 1991; Fernández-Monrás <b>et</b> <b>al.</b> 1990; Catalá Barceló MT 1998; Fernández-Natal and Alcoba-Leza 1996; Calduch Broseta JV 2003; Rabadan and Vilalta 1989; Rubin <b>et</b> <b>al.</b> 1981; Nedunchezian <b>et</b> <b>al.</b> 1994; Pitrak and Gindorf 1989; Bonner <b>et</b> <b>al.</b> 1983; Newman <b>et</b> <b>al.</b> 1993; Namdari <b>et</b> <b>al.</b> 2000; Patel <b>et</b> <b>al.</b> 2009; Wagner <b>et</b> <b>al.</b> 1995; Siegel and Rogers 1982; McCleskey <b>et</b> <b>al.</b> 1986; Florman <b>et</b> <b>al.</b> 1990; West <b>et</b> <b>al.</b> 1998; Klontz 1990; Hughes <b>et</b> <b>al.</b> 1978; Restrepo <b>et</b> <b>al.</b> 2006; Safrin <b>et</b> <b>al.</b> 1988; Fearrington <b>et</b> <b>al.</b> 1974; Shannon and Kimbrough 2006; Platia and Vosti 1980; Kontoyiannis <b>et</b> <b>al.</b> 1995; Shelton <b>et</b> <b>al.</b> 1993; Crump <b>et</b> <b>al.</b> 2003; Naidu <b>et</b> <b>al.</b> 1993; Morgan <b>et</b> <b>al.</b> 1985; Lukinmaa <b>et</b> <b>al.</b> 2006; Blanche and Sicard 1994; Moinard <b>et</b> <b>al.</b> 1989; Laudat <b>et</b> <b>al.</b> 1997; Raultin and de La Roy, 1981; Couzigou <b>et</b> <b>al.</b> 2007; Issack <b>et</b> <b>al.</b> 2008; Kerketta <b>et</b> <b>al.</b> 2002; Thomas <b>et</b> <b>al.</b> 1996; Lalitha <b>et</b> <b>al.</b> 1986; George <b>et</b> <b>al.</b> 2013; Raju <b>et</b> <b>al.</b> 1990; Khan <b>et</b> <b>al.</b> 2013; Toeg <b>et</b> <b>al.</b> 1990; Rudensky <b>et</b> <b>al.</b> 1993; Farina <b>et</b> <b>al.</b> 1999; Piersimoni <b>et</b> <b>al.</b> 1991; Ismail <b>et</b> <b>al.</b> 2001; Dhar <b>et</b> <b>al.</b> 1989, 2004; Phetsouvanh <b>et</b> <b>al.</b> 2008; Feghali and Adib 2011; Tan <b>et</b> <b>al.</b> 1994; Deris and Leow 2009; Whittaker 2013; Stypulkowska-Misiurewicz <b>et</b> <b>al.</b> 2006; Albuquerque <b>et</b> <b>al.</b> 2013; El-Hiday and Khan 2006; Khan <b>et</b> <b>al.</b> 2007; Strumbelj <b>et</b> <b>al.</b> 2005; Wiström 1989; Lin <b>et</b> <b>al.</b> 1996; Ko <b>et</b> <b>al.</b> 1998; Lee <b>et</b> <b>al.</b> 1993; Chang-Chien 2006; Tsai and Huang 2009; Chan <b>et</b> <b>al.</b> 1994; Yang <b>et</b> <b>al.</b> 2008; Cheng <b>et</b> <b>al.</b> 2004; Tsai <b>et</b> <b>al.</b> 2004; Wang <b>et</b> <b>al.</b> 1991; Laosombat <b>et</b> <b>al.</b> 1996; Punpanich <b>et</b> <b>al.</b> 2011; Thisyakorn and Reinprayoon 1990; Luxsameesathaporn <b>et</b> <b>al.</b> 2012; Suankratay <b>et</b> <b>al.</b> 2001; Wiwatworapan and Insiripong 2008; Boukadida <b>et</b> <b>al.</b> 1993; Lan <b>et</b> <b>al.</b> 2014; Geneste <b>et</b> <b>al.</b> 1995; Yang <b>et</b> <b>al.</b> 2011; Thomas <b>et</b> <b>al.</b> 2007; Ou <b>et</b> <b>al.</b> 2003; Lee <b>et</b> <b>al.</b> 2007; Thamlikitkul 1990; Jesudason <b>et</b> <b>al.</b> 1991). The majority of articles were case reports, the largest series including 69 cases of bacteraemia (Ou <b>et</b> <b>al.</b> 2003). The first case was described in the USA in 1974 (Fearrington <b>et</b> <b>al.</b> 1974). One hundred and fifty-six cases (45  %) originated from Taiwan, 60 / 350 (20  %) from the USA and 21 / 350 (6  %) from Spain. Although NOVC strains are frequently found in coastal waters, only two cases {{have been reported in}} Africa. Two possible explanations are under-diagnosis due to lack of resources, and the non reporting of clinical cases. Including our own case report, 12 cases of NOVC bacteraemia have been published in France, in summer or autumn, including four imported cases from Tunisia (2), Morocco (1) and Senegal (1) (Farmachidi <b>et</b> <b>al.</b> 2003; Blanche and Sicard 1994; Moinard <b>et</b> <b>al.</b> 1989; Laudat <b>et</b> <b>al.</b> 1997; Raultin and de La Roy, 1981; Couzigou <b>et</b> <b>al.</b> 2007).|$|R
30|$|Because of its {{popularity}} for hybrid rice production, both {{the parents and}} the hybrid have been extensively used for genetics and genomics studies during the past four decades. In the first report of resequencing multiple varieties, both parents of SY 63 were used among 20 diverse varieties for resequencing of 100  Mb of the unique fraction of the genome (McNally <b>et</b> <b>al.</b> 2009). It was found that large components of the japonica genome were introgressed into both of the parents, specifically, on chromosome 1 of ZS 97 and chromosome 6 of MH 63. Those components contribute greatly to genes controlling heterosis (Yu <b>et</b> <b>al.</b> 1997; Hua <b>et</b> <b>al.</b> 2002; Li <b>et</b> <b>al.</b> 2008; Li <b>et</b> <b>al.</b> 2008; Zhou <b>et</b> <b>al.</b> 2012; Shen <b>et</b> <b>al.</b> 2014; Zhu <b>et</b> <b>al.</b> 2016). Other studies on the association of QTLs and traits included plant height (Xing <b>et</b> <b>al.</b> 2001; Guo <b>et</b> <b>al.</b> 2002; Yu <b>et</b> <b>al.</b> 2002; Guo <b>et</b> <b>al.</b> 2003; Shen <b>et</b> <b>al.</b> 2014), heading date (Xing <b>et</b> <b>al.</b> 2001; Guo <b>et</b> <b>al.</b> 2002; Guo <b>et</b> <b>al.</b> 2003; Yu <b>et</b> <b>al.</b> 2002; Zhu <b>et</b> <b>al.</b> 2016), fertility-restoring genes (He <b>et</b> <b>al.</b> 2002), seedling traits (Cui <b>et</b> <b>al.</b> 2002; Cui <b>et</b> <b>al.</b> 2002; Cui <b>et</b> <b>al.</b> 2010; Zhu <b>et</b> <b>al.</b> 2016), leaf shape (Li <b>et</b> <b>al.</b> 2008), grain quality (Tan <b>et</b> <b>al.</b> 1999; Tan <b>et</b> <b>al.</b> 2001; Xing <b>et</b> <b>al.</b> 2001; Ge <b>et</b> <b>al.</b> 2005; Zheng <b>et</b> <b>al.</b> 2008 a; Zheng <b>et</b> <b>al.</b> 2008 b), yield-related traits (Yu <b>et</b> <b>al.</b> 1997; Guo <b>et</b> <b>al.</b> 2002; Hua <b>et</b> <b>al.</b> 2002; Xing <b>et</b> <b>al.</b> 2002; Cui <b>et</b> <b>al.</b> 2003; Guo <b>et</b> <b>al.</b> 2003; Xue <b>et</b> <b>al.</b> 2008; Li <b>et</b> <b>al.</b> 2008; Xing <b>et</b> <b>al.</b> 2008; Liu <b>et</b> <b>al.</b> 2010; Liu <b>et</b> <b>al.</b> 2010; Zhou <b>et</b> <b>al.</b> 2012), disease resistance (Han <b>et</b> <b>al.</b> 2002; Chen <b>et</b> <b>al.</b> 2002; Yang <b>et</b> <b>al.</b> 2003; Li <b>et</b> <b>al.</b> 2010; Kou <b>et</b> <b>al.</b> 2010), tolerance of nitrogen deficiency (Lian <b>et</b> <b>al.</b> 2005; Wei <b>et</b> <b>al.</b> 2012), and drought tolerance (Lian <b>et</b> <b>al.</b> 2005; Wei <b>et</b> <b>al.</b> 2012).|$|R
50|$|Stitt {{acquired}} the film rights to Grendel in 1978, and work was commenced at Melbourne <b>Al</b> <b>et</b> al. Studios the following year. The film was {{conceived as a}} coproduction with producer Phillip Adams, {{under the banner of}} Animation Australia. Although completed in 1981, it was not released in US theatres until the spring of 1982. Because of its limited appeal, broadcasting of the film was largely restricted to art theatres in urban centres.|$|E
5000|$|The park ranges in {{altitude}} from 137 m {{above sea}} level immediately below Devil’s Nose to just over 328 m asl in the south eastern corner of the park. 76% of the park lies above the 24 m contour. The landform of the park {{has been described as}} [...] "a hilly upland with broad crests and dissected slopes" [...] (Lauet <b>al</b> <b>et,</b> 1977). The northern section is a dissected plateau due to the South Para River, which has formed steep sloped valleys and narrow ridge tops; the central reserve area is an undissected plateau; and the southern area is dominated by Mack Creek.|$|E
3000|$|... 3. Roseberg <b>AL</b> <b>et</b> al. Patients readmitted to ICUs: A {{systematic}} review {{of risk factors}} and outcomes. Chest 2000; 118 (2): 492 - 502.|$|E
30|$|Inter-rater {{reliability}} was reported for 12 (48 %) {{of the studies}} (Barsuk <b>et</b> <b>al.</b> 2009 a; Barsuk <b>et</b> <b>al.</b> 2009 c; Dong <b>et</b> <b>al.</b> 2010; Evans <b>et</b> <b>al.</b> 2009; Huang <b>et</b> <b>al.</b> 2009; Lee <b>et</b> <b>al.</b> 2009; Millington <b>et</b> <b>al.</b> 2009; Murphy <b>et</b> <b>al.</b> 2008; Rosen <b>et</b> <b>al.</b> 2009; Kilbourne <b>et</b> <b>al.</b> 2009; Stone <b>et</b> <b>al.</b> 2010; Xiao <b>et</b> <b>al.</b> 2007), reporting a range of reliability coefficients and absolute agreement [range 0.43 (Millington <b>et</b> <b>al.</b> 2009) to 0.97 (Evans <b>et</b> <b>al.</b> 2009)]. Only 12 studies (48 %) specified the process used for content validation (Velmahos <b>et</b> <b>al.</b> 2004; Barsuk <b>et</b> <b>al.</b> 2009 a; Barsuk <b>et</b> <b>al.</b> 2009 c; Costello <b>et</b> <b>al.</b> 2008; Dong <b>et</b> <b>al.</b> 2010; Evans <b>et</b> <b>al.</b> 2009; Huang <b>et</b> <b>al.</b> 2009; Lee <b>et</b> <b>al.</b> 2009; Rosen <b>et</b> <b>al.</b> 2009; Wall <b>et</b> <b>al.</b> 2005; Kilbourne <b>et</b> <b>al.</b> 2009; Coopersmith <b>et</b> <b>al.</b> 2002).|$|R
30|$|Although breast {{reconstruction}} {{rates have}} increased over time, they remain relatively low, ranging from 5 to 42  % in population-based and institution-based studies (Brennan and Spillane 2013; Platt <b>et</b> <b>al.</b> 2011; Wilkins and Alderman 2004). These {{studies have found}} that reconstruction rates are significantly lower in African American compared to Caucasian women (Alderman <b>et</b> <b>al.</b> 2009, 2011; Butler <b>et</b> <b>al.</b> 2015; Greenberg <b>et</b> <b>al.</b> 2008; Hershman <b>et</b> <b>al.</b> 2012; Katz <b>et</b> <b>al.</b> 2005; Merchant <b>et</b> <b>al.</b> 2015; Morrow <b>et</b> <b>al.</b> 2005; Reuben <b>et</b> <b>al.</b> 2009; Rosson <b>et</b> <b>al.</b> 2008; Rowland <b>et</b> <b>al.</b> 2000; Tseng <b>et</b> <b>al.</b> 2004; Yang <b>et</b> <b>al.</b> 2013 a, b), a disparity that has been attributed to racial differences in access to breast reconstructive services (Agarwal <b>et</b> <b>al.</b> 2011; Enewold <b>et</b> <b>al.</b> 2014; Greenberg <b>et</b> <b>al.</b> 2008; Katz <b>et</b> <b>al.</b> 2005; Offodile <b>et</b> <b>al.</b> 2015; Rowland <b>et</b> <b>al.</b> 1993; Wexelman <b>et</b> <b>al.</b> 2014) secondary to lower socioeconomic status (Alderman <b>et</b> <b>al.</b> 2003; Greenberg <b>et</b> <b>al.</b> 2008; Joslyn 2005; Katz <b>et</b> <b>al.</b> 2005; Kruper <b>et</b> <b>al.</b> 2011 a; Offodile <b>et</b> <b>al.</b> 2015; Wexelman <b>et</b> <b>al.</b> 2014) and no or inadequate insurance (Alderman <b>et</b> <b>al.</b> 2006; Bradley <b>et</b> <b>al.</b> 2012; Enewold <b>et</b> <b>al.</b> 2014; Wexelman <b>et</b> <b>al.</b> 2014).|$|R
30|$|PNPLA 3 polymorphisms {{have been}} {{reported}} to be associated with hepatic steatosis, inflammation, fibrosis, and carcinogenesis in NAFLD (Romeo <b>et</b> <b>al.</b> 2008; Rotman <b>et</b> <b>al.</b> 2010; Valenti <b>et</b> <b>al.</b> 2010; Sookoian and Pirola 2011; Burza <b>et</b> <b>al.</b> 2012; Kawaguchi <b>et</b> <b>al.</b> 2012; Kitamoto <b>et</b> <b>al.</b> 2013). PNPLA 3 polymorphisms have also been reported to be associated with hepatic steatosis, fibrosis, treatment response, and carcinogenesis in CHC (Valenti <b>et</b> <b>al.</b> 2011; Trepo <b>et</b> <b>al.</b> 2011; Cai <b>et</b> <b>al.</b> 2011; Valenti <b>et</b> <b>al.</b> 2012; Clark <b>et</b> <b>al.</b> 2012; Dunn <b>et</b> <b>al.</b> 2014; Ezzikouri <b>et</b> <b>al.</b> 2014; Moritou <b>et</b> <b>al.</b> 2013; Zampino <b>et</b> <b>al.</b> 2013; Trepo <b>et</b> <b>al.</b> 2014; Sato <b>et</b> <b>al.</b> 2013). However, several reports have not found an association of PNPLA 3 polymorphisms with fibrosis and carcinogenesis in CHC (Trepo <b>et</b> <b>al.</b> 2011; Nischalke <b>et</b> <b>al.</b> 2011; Rembeck <b>et</b> <b>al.</b> 2012; Miyashita <b>et</b> <b>al.</b> 2012; Takeuchi <b>et</b> <b>al.</b> 2013; Nakamura <b>et</b> <b>al.</b> 2013; Guyot <b>et</b> <b>al.</b> 2013).|$|R
30|$|In general, SAP is {{synthesized}} by grafting or grafting-crosslinking copolymerization. The monomers used in grafting copolymerization include {{acrylic acid}} and acrylamide (Li et al. 2007; Teli and Waghmare 2009), while N,N-methylene-bisacrylamide (MBA), trimethyl propane triacrylate, and 1, 4 -butadienol dimethacrylate {{are used as}} crosslinkers (Swantomo et al. 2008). Commonly used initiators are persulfate salts, hydrogen peroxide (Moad and Solomon 2006), and cerium salts (<b>Al</b> <b>et</b> al. 2008).|$|E
30|$|Cyclic Nucleotide Phosphodiesterases (PDEs) are encoded by 21 {{different}} genes {{grouped into}} 11 gene families based on sequence similarity, mode of regulation, and specificity for cAMP or cGMP as substrate (Francis, et al. 2011; Lerner and Epstein 2006). There is considerable interest in PDEs owing to studies showing {{them to be}} excellent candidate targets for treating {{a wide range of}} illnesses including hematological malignancies, osteoporosis and inflammatory and autoimmune diseases (Epstein 2012; Francis, et <b>al.</b> <b>et</b> al. 2011; Lerner and Epstein 2006; Vang, et <b>al.</b> <b>et</b> al. 2010). Catalytic subunits of PDE 6, a cGMP-specific PDE, were thought to be photoreceptor-specific, localized exclusively to the outer segment of rods and cones in the eye, where they are crucial for the transduction of light (Stryer 1986; Zhang and Cote 2005). The rod outer segment (ROS) is a dual membrane system composed of about 2000 disks surrounded by a physically separate plasma membrane. The disks contain rhodopsin, PDE 6 and transducin. The plasma membrane contains a cGMP-gated sodium channel. In the dark, the ROS contains an unusally high concentration of cGMP (≈ 70  μM), which activates the sodium channel and depolarizes the membrane. When light impinges on rhodopsin on the disks, it photoisomerizes its chromophore, which in turn activates the GTP-binding protein, transducin, which activates the catalytic activity of PDE 6 by dissociating its inhibitory γ subunits. PDE 6 then very rapidly reduces the cGMP concentration leading to inactivation of the sodium channels and hyperpolarization of the plasma membrane which is conveyed to the synapse {{at the other end of}} the rod and communicated to other cells of the retina (Stryer 1986; Zhang and Cote 2005). In the human rod, PDE 6 is composed of two large (≈ 99  kDa) catalytic subunits, α and β, encoded by the PDE 6 A and PDE 6 B genes respectively, two small (≈ 11  kDa) inhibitory γ subunits encoded by PDE 6 G, and a small (≈ 17  kDa) δ regulatory subunit encoded by PDE 6 D. The human cone PDE 6 contains two α’ catalytic subunits encoded by PDE 6 C, two inhibitory γ subunits encoded by PDE 6 H, and a regulatory δ subunit encoded by PDE 6 D (Ionita and Pittler 2007). The PDE 6 D-encoded δ subunit (PDE 6 δ) is not specific to PDE 6 in that it binds to other enzymes and is expressed in other tissues (Zhang, et al. 2004). Its function as part of the PDE 6 enzyme is unclear, although it is generally found to be bound to the soluble fraction of PDE 6 in retina extracts and may play a role in transport of PDE 6 to the disks or its translocation to the plasma membrane (Cook, et al. 2001; Zhang, et <b>al.</b> <b>et</b> al. 2007). PDE 6 δ has also been shown to function as a cytosolic farnesyl-binding chaperone protein for ras, which facilitates ras trafficking and signaling (Chandra, et al. 2012). The γ inhibitory subunit of PDE 6 is also expressed in other tissues such as lung and kidney cells (Guo and Ruoho 2008; Tate, et <b>al.</b> <b>et</b> al. 2002) and has been suggested to play a role in the activation of MAP kinase by epidermal growth factor signaling (Wan, et al. 2003). PDE 6 catalytic activity has also been reported in chick pineal gland where it is believed to mediate the light induced inhibition of melatonin synthesis (Holthues and Vollrath 2004; Morin, et <b>al.</b> <b>et</b> al. 2001). In contrast to humans, in chick, both in rods and pineal glands, the catalytic activity of PDE 6 appears to be comprised of homodimers of two PDE 6 B-encoded β subunits, with no evidence for the expression of PDE 6 A-encoded α subunits present in these chick tissues (Huang, et al. 2004; Morin, et <b>al.</b> <b>et</b> al. 2001). Inasmuch as cGMP has been shown to regulate proliferation and apoptosis of breast cancer cells (Saravani, et al. 2012; Tinsley, et <b>al.</b> <b>et</b> al. 2011), we examined breast cancer cells for the expression of PDE 6 genes. In this paper we show significant expression of PDE 6 B, PDE 6 C, and PDE 6 D, in human breast cancer cell lines and patients’ breast cancer tissues.|$|E
30|$|Older workers’ {{unemployment}} is mainly characterized by difficulties {{in finding a}} new job {{for those who have}} lost their jobs (Axelrad et <b>al.</b> <b>et</b> al. 2013). This fact seems counter-intuitive because older workers have the experience and accumulated knowledge that the younger working population lacks. The losses to society and the individuals are substantial because life expectancy is increasing, the retirement age is rising in many countries, and people are generally in good health (Axelrad et al. 2013; Vodopivec and Dolenc 2008).|$|E
30|$|Epidemiological {{studies on}} the {{association}} between physical activity and mammographic density have reported inconsistent results (Lopez <b>et</b> <b>al.</b> 2003; Monninkhof <b>et</b> <b>al.</b> 2007; Irwin <b>et</b> <b>al.</b> 2006; Masala <b>et</b> <b>al.</b> 2009; Siozon <b>et</b> <b>al.</b> 2006; Gram <b>et</b> <b>al.</b> 1999; Suijkerbuijk <b>et</b> <b>al.</b> 2006; Reeves <b>et</b> <b>al.</b> 2007; Samimi <b>et</b> <b>al.</b> 2008; Conroy <b>et</b> <b>al.</b> 2010; Peters <b>et</b> <b>al.</b> 2008). A few have reported a statistically significant inverse association between physical activity and mammographic density (Masala <b>et</b> <b>al.</b> 2009; Lopez <b>et</b> <b>al.</b> 2003; Irwin <b>et</b> <b>al.</b> 2006; Monninkhof <b>et</b> <b>al.</b> 2007). But most studies have {{found no evidence of}} an association (Peters <b>et</b> <b>al.</b> 2008; Suijkerbuijk <b>et</b> <b>al.</b> 2006; Siozon <b>et</b> <b>al.</b> 2006; Reeves <b>et</b> <b>al.</b> 2007; Samimi <b>et</b> <b>al.</b> 2008; Conroy <b>et</b> <b>al.</b> 2010; Gram <b>et</b> <b>al.</b> 1999). A number of these studies have reported a positive association between physical activity and mammographic density that attenuated after adjustments for BMI (Peters <b>et</b> <b>al.</b> 2008; Reeves <b>et</b> <b>al.</b> 2007).|$|R
30|$|Proteasome phosphorylations {{are seen}} in almost every {{large-scale}} phosphoproteomic dataset. More importantly, the proteasome is dynamically phosphorylated {{in a variety of}} physiological and pathological processes, including development and stem/progenitor cell differentiation (Brill <b>et</b> <b>al.,</b> 2009; Rigbolt <b>et</b> <b>al.,</b> 2011; Goswami <b>et</b> <b>al.,</b> 2012), cell cycle (Beausoleil <b>et</b> <b>al.,</b> 2006; Dephoure <b>et</b> <b>al.,</b> 2008; Nagano <b>et</b> <b>al.,</b> 2009; Olsen <b>et</b> <b>al.,</b> 2010; Kettenbach <b>et</b> <b>al.,</b> 2011; Guo <b>et</b> <b>al.,</b> 2016), DNA damage response (Matsuoka <b>et</b> <b>al.,</b> 2007; Stokes <b>et</b> <b>al.,</b> 2007), stress responses (Um <b>et</b> <b>al.,</b> 2010; Wang <b>et</b> <b>al.,</b> 2014), immune signaling (Bose <b>et</b> <b>al.,</b> 2001; Bose <b>et</b> <b>al.,</b> 2004; Mayya <b>et</b> <b>al.,</b> 2009; Weintz <b>et</b> <b>al.,</b> 2010; Wu <b>et</b> <b>al.,</b> 2012), metabolic changes (Bardag-Gorce <b>et</b> <b>al.,</b> 2004; Zhang <b>et</b> <b>al.,</b> 2007 b; Trost <b>et</b> <b>al.,</b> 2012), neuronal activity (Djakovic <b>et</b> <b>al.,</b> 2009; Bingol <b>et</b> <b>al.,</b> 2010; Djakovic <b>et</b> <b>al.,</b> 2012; Hamilton <b>et</b> <b>al.,</b> 2012; Jarome <b>et</b> <b>al.,</b> 2013; Jarome <b>et</b> <b>al.,</b> 2016; Li <b>et</b> <b>al.,</b> 2016), hormones and growth factor signaling (Kim <b>et</b> <b>al.,</b> 2009; Pan <b>et</b> <b>al.,</b> 2009; Lundby <b>et</b> <b>al.,</b> 2013; Williams <b>et</b> <b>al.,</b> 2016), and oncogenesis (Rush <b>et</b> <b>al.,</b> 2005; Rikova <b>et</b> <b>al.,</b> 2007; Guo <b>et</b> <b>al.,</b> 2008; Luo <b>et</b> <b>al.,</b> 2008; Choudhary <b>et</b> <b>al.,</b> 2009; Eang <b>et</b> <b>al.,</b> 2009; Iliuk <b>et</b> <b>al.,</b> 2010; Johnson <b>et</b> <b>al.,</b> 2012; Trost <b>et</b> <b>al.,</b> 2012; Yuan <b>et</b> <b>al.,</b> 2013). Although the functional roles of proteasome phosphorylation in these processes are largely uncharacterized, increasing evidence indicates that the 26 S proteasome is not a uniform and static complex acting passively as a “cellular trashcan”. Rather, the proteasome itself is fine-tuned by reversible phosphorylation in response to intra- and extra-cellular signals, which can be a prerequisite or feedback mechanism for a wide spectrum of cellular events that depend on proteasome function.|$|R
30|$|The {{risk for}} the {{development}} of breast cancer in relation to alcohol consumption has been thoroughly studied. Alcohol intake, both light and heavy drinking, is now identified as a risk factor for pre- and postmenopausal breast cancer (Singletary and Gapstur 2001;Hamajima <b>et</b> <b>al.</b> 2002;Pelucchi <b>et</b> <b>al.</b> 2011;Chen <b>et</b> <b>al.</b> 2011;Seitz <b>et</b> <b>al.</b> 2012). If and how alcohol consumption is associated with survival and disease recurrence is, however, not yet completely understood. The results from previous studies are inconsistent. The majority of studies report no association between alcohol consumption and overall survival (Holmes <b>et</b> <b>al.</b> 1999;Dal Maso <b>et</b> <b>al.</b> 2008;Hellmann <b>et</b> <b>al.</b> 2010;Kwan <b>et</b> <b>al.</b> 2010;Ali <b>et</b> <b>al.</b> 2014) or breast cancer-specific survival (Dal Maso <b>et</b> <b>al.</b> 2008;Harris <b>et</b> <b>al.</b> 2012;Holm <b>et</b> <b>al.</b> 2013). Some studies report a protective effect from alcohol consumption on overall survival (Harris <b>et</b> <b>al.</b> 2012;Reding <b>et</b> <b>al.</b> 2008;Barnett <b>et</b> <b>al.</b> 2008;Flatt <b>et</b> <b>al.</b> 2010) and breast cancer-specific survival (Ali <b>et</b> <b>al.</b> 2014;Reding <b>et</b> <b>al.</b> 2008;Flatt <b>et</b> <b>al.</b> 2010;Newcomb <b>et</b> <b>al.</b> 2013), while other studies report higher breast cancer-specific mortality (Kwan <b>et</b> <b>al.</b> 2010;Allemani <b>et</b> <b>al.</b> 2011;Vrieling <b>et</b> <b>al.</b> 2012). Five studies have investigated the association between alcohol consumption and recurrence of breast cancer (Kwan <b>et</b> <b>al.</b> 2010;Holm <b>et</b> <b>al.</b> 2013;Flatt <b>et</b> <b>al.</b> 2010;Vrieling <b>et</b> <b>al.</b> 2012;Kwan <b>et</b> <b>al.</b> 2013), and two of these report an increased risk of breast cancer recurrence (Kwan <b>et</b> <b>al.</b> 2010;Holm <b>et</b> <b>al.</b> 2013).|$|R
40|$|Aim of {{this work}} is to gather {{information}} about correct process of young horse training. This work presents opinions of specialists (for example Záliš, Bílek et <b>al.</b> <b>et</b> al., Paalman, Dillon, Beran and others) and offers view of traditional approach to young horses with addition of modern science´s findings. In the beginning {{of this work}} will be covered the topic of imprinting and weaning and impact of those events on life and work of a young horse. Further more, this work addresses the topic of basic training, under the saddle and in harness...|$|E
40|$|BBB {{blood brain barrier}} C(integer), e. g. C(5) {{the number}} of carbon atoms in an organic {{compound}} C-integer, e. g. C- 5 a specific carbon atom in an organic compound 14 C carbon- 14, a radioactive isomer to the common carbon- 12 CNS central nervous system E from German Entegen, which means “opposite”. Through the Cahn-Ingold-Prelog-rules the functional groups around a double bond are valued, and if high priority groups {{through a number of}} sequences are on opposite sides, the compound are named E- [...] . If they are on the same side it is called Z, which means Zuzammen, meaning “together”. et <b>al.</b> <b>et</b> alii, and other...|$|E
40|$|Summary: Renal inulin {{clearance}} {{remains the}} {{standard by which}} other methods of measuring glomerular filtration rate are judged. A fully automated enzymatic assay capable of use with linear configuration inulin was recently published (Summerfield <b>AL,</b> <b>et</b> al. Clin Chem 1993; 39 : 2333 — 7). Sinistrin, a readily soluble preparation of poly-fructan with side branching, is more suitable for clinical use and far more widely used in Europe. By modifying the incubation phase of samples with inulinase, incorporating a kinetic modification to the method of fructose analysis, and increasing the buffer strengths, we report a fully automated system, with minimal sample prehandling capable of complete sinistrin hydrolysis, and adapted for use on the Cobas Mira...|$|E
30|$|Recently, the risk-benefit {{ratio of}} HT was reassessed for various ages and time {{intervals}} since menopause onset. The North American Menopause Society (NAMS) (NAMS 2012) proposed that {{duration of treatment}} {{should be limited to}} younger women up to the age of 50 to 59 years; beyond which, HT is associated with increased risks. Similar recommendations were issued by the International Menopause Society (IMS) in 2011 (Sturdee <b>et</b> <b>al.</b> 2011), which considered HT as a first-line therapy choice for climacteric symptoms. Finally, a global consensus on the use of HT was obtained by The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society (de Villiers <b>et</b> <b>al.</b> 2013). They stated that HT “is the most effective treatment for vasomotor symptoms associated with menopause at any age, but benefits are more likely to outweigh risks for symptomatic women before the age of 60 years or within 10 years after menopause”. Although some HT restrictions have been withdrawn, there is still a considerable need for non-hormonal treatment alternatives, especially for elderly post-menopausal women or cancer patients of both genders. Therefore, this present work aimed to assess the risk-benefit ratio of various non-hormonal treatment options. Among them, four non-hormonal treatments appear to have significant evidence for a beneficial effect in treating vasomotor climacteric or androgen-ablation symptoms, although some studied the effects over a period shorter than 12 weeks: gabapentin/pregabalin (Loprinzi <b>et</b> <b>al.</b> 2002 a; Guttuso <b>et</b> <b>al.</b> 2003; Reddy <b>et</b> <b>al.</b> 2006; Loprinzi <b>et</b> <b>al.</b> 2007; Butt <b>et</b> <b>al.</b> 2008; Saadati <b>et</b> <b>al.</b> 2013; Agarwal <b>et</b> <b>al.</b> 2014; Pinkerton <b>et</b> <b>al.</b> 2014; Loprinzi <b>et</b> <b>al.</b> 2010; Pandya <b>et</b> <b>al.</b> 2004; Pandya <b>et</b> <b>al.</b> 2005; Bordeleau <b>et</b> <b>al.</b> 2010; Loprinzi <b>et</b> <b>al.</b> 2009; Moraska <b>et</b> <b>al.</b> 2010), SSRIs (Stearns <b>et</b> <b>al.</b> 2003; Stearns <b>et</b> <b>al.</b> 2005; Simon <b>et</b> <b>al.</b> 2013; Huang <b>et</b> <b>al.</b> 2013; Stearns <b>et</b> <b>al.</b> 2000; Gordon <b>et</b> <b>al.</b> 2006; Grady <b>et</b> <b>al.</b> 2007; Kerwin <b>et</b> <b>al.</b> 2007; Aedo <b>et</b> <b>al.</b> 2011; Kimmick <b>et</b> <b>al.</b> 2006; Wu <b>et</b> <b>al.</b> 2009; Suvanto-Luukkonen <b>et</b> <b>al.</b> 2005; Oktem <b>et</b> <b>al.</b> 2007; Loprinzi <b>et</b> <b>al.</b> 2002 b; Barton <b>et</b> <b>al.</b> 2010; Barton <b>et</b> <b>al.</b> 2003; Defronzo Dobkin <b>et</b> <b>al.</b> 2009; Freedman <b>et</b> <b>al.</b> 2011; Freeman <b>et</b> <b>al.</b> 2011; Carpenter <b>et</b> <b>al.</b> 2012; Ensrud <b>et</b> <b>al.</b> 2012), venlafaxine/desvenlafaxine (Evans <b>et</b> <b>al.</b> 2005; Loprinzi <b>et</b> <b>al.</b> 2006; Loprinzi <b>et</b> <b>al.</b> 1998; Carpenter <b>et</b> <b>al.</b> 2007; Quella <b>et</b> <b>al.</b> 1999; Loprinzi <b>et</b> <b>al.</b> 2000; Loibl <b>et</b> <b>al.</b> 2007; Buijs <b>et</b> <b>al.</b> 2009; Boekhout <b>et</b> <b>al.</b> 2011; Bordeleau <b>et</b> <b>al.</b> 2010; Vitolins <b>et</b> <b>al.</b> 2013; Speroff <b>et</b> <b>al.</b> 2008; Archer <b>et</b> <b>al.</b> 2009 a; Archer <b>et</b> <b>al.</b> 2009 b; Cheng <b>et</b> <b>al.</b> 2013; Bouchard <b>et</b> <b>al.</b> 2012; Pinkerton <b>et</b> <b>al.</b> 2013), and CREs (Drewe <b>et</b> <b>al.</b> 2013; Lopatka <b>et</b> <b>al.</b> 2007; Vermes <b>et</b> <b>al.</b> 2005; Liske <b>et</b> <b>al.</b> 2002; Frei-Kleiner <b>et</b> <b>al.</b> 2005; Schellenberg <b>et</b> <b>al.</b> 2012; Osmers <b>et</b> <b>al.</b> 2005; Ross 2012; Newton <b>et</b> <b>al.</b> 2006; Geller <b>et</b> <b>al.</b> 2009; Stoll 1987; Wuttke <b>et</b> <b>al.</b> 2003; Nappi <b>et</b> <b>al.</b> 2005; Bai <b>et</b> <b>al.</b> 2007; Uebelhack <b>et</b> <b>al.</b> 2006; Briese <b>et</b> <b>al.</b> 2007; Oktem <b>et</b> <b>al.</b> 2007; Huang <b>et</b> <b>al.</b> 2013; Pockaj <b>et</b> <b>al.</b> 2004; Jacobson <b>et</b> <b>al.</b> 2001; Pockaj <b>et</b> <b>al.</b> 2006; Hernández Munoz & Pluchino 2003; Rostock <b>et</b> <b>al.</b> 2011).|$|R
30|$|Although few {{previous}} {{reports have}} shown the characteristics of imaging findings of primary hepatic carcinoid tumors owing to their rarity, it has been thought, based on previous reports and our present cases, that the relatively characteristic imaging findings include cystic areas with hemorrhagic components (Takayasu <b>et</b> <b>al.</b> 1992; Abdel Wahab <b>et</b> <b>al.</b> 2006; Komatsuda <b>et</b> <b>al.</b> 2005; Ulusan <b>et</b> <b>al.</b> 2005; Touloumis <b>et</b> <b>al.</b> 2008; Imaoka <b>et</b> <b>al.</b> 1993; Fujino <b>et</b> <b>al.</b> 1998; Oh <b>et</b> <b>al.</b> 1998; Kehagias <b>et</b> <b>al.</b> 1999; Hirata <b>et</b> <b>al.</b> 2002; Aoki <b>et</b> <b>al.</b> 1992; Yeung <b>et</b> <b>al.</b> 2008; Shih <b>et</b> <b>al.</b> 2005) and early enhanced solid areas (Iwao <b>et</b> <b>al.</b> 2001; Lin <b>et</b> <b>al.</b> 2009; Takayasu <b>et</b> <b>al.</b> 1992; Abdel Wahab <b>et</b> <b>al.</b> 2006; Komatsuda <b>et</b> <b>al.</b> 2005; Ulusan <b>et</b> <b>al.</b> 2005; Touloumis <b>et</b> <b>al.</b> 2008; Iimuro <b>et</b> <b>al.</b> 2002; Gao J <b>et</b> <b>al.</b> 2011; Shah <b>et</b> <b>al.</b> 2007).|$|R
30|$|The donor-sites {{used for}} the {{osteochondral}} graft harvesting varied across the studies, including: margins of the medial femoral trochlea (condyle) (Hangody <b>et</b> <b>al.</b> 2010; Gudas <b>et</b> <b>al.</b> 2005; Ahmad & Jones 2015; de l'Escalopier <b>et</b> <b>al.</b> 2015; Gautier <b>et</b> <b>al.</b> 2002; Hangody <b>et</b> <b>al.</b> 2001 a; Hangody <b>et</b> <b>al.</b> 2008; Jakob <b>et</b> <b>al.</b> 2002; Lee <b>et</b> <b>al.</b> 2003; Quarch <b>et</b> <b>al.</b> 2014); margins of the lateral femoral trochlea (condyle) (Hangody <b>et</b> <b>al.</b> 2010; Reddy <b>et</b> <b>al.</b> 2007; Gudas <b>et</b> <b>al.</b> 2005; Ahmad & Jones 2015; Al-Shaikh <b>et</b> <b>al.</b> 2002; Baltzer & Arnold 2005; de l'Escalopier <b>et</b> <b>al.</b> 2015; Gautier <b>et</b> <b>al.</b> 2002; Hangody <b>et</b> <b>al.</b> 2001 a; Hangody <b>et</b> <b>al.</b> 2008; Jakob <b>et</b> <b>al.</b> 2002; Kim <b>et</b> <b>al.</b> 2012; Kock <b>et</b> <b>al.</b> 2010; Koulalis <b>et</b> <b>al.</b> 2004; Reverte-Vinaixa <b>et</b> <b>al.</b> 2013; Valderrabano <b>et</b> <b>al.</b> 2009); minimal weight-bearing areas of the patellofemoral joint (Atik <b>et</b> <b>al.</b> 2005); intercondylar notch area (Reddy <b>et</b> <b>al.</b> 2007; Atik <b>et</b> <b>al.</b> 2005; Hangody <b>et</b> <b>al.</b> 2008); upper tibio-fibular joint (Espregueira-Mendes <b>et</b> <b>al.</b> 2012).|$|R
30|$|Considerable {{epidemiologic}} {{evidence has}} been amassed over the past 25  years demonstrating an association between increased exposure to LAN and increased rates of breast cancer (Flynn-Evans, et al. 2009; Kloog, et <b>al.</b> <b>et</b> al. 2010; Stevens 2009 a,b). Specific evidence for this includes increased incidence of breast cancer among women who work non-day shifts, lower incidence of breast cancer among totally blind women, an inverse relationship between breast cancer incidence and sleep duration, and a correlation between increased incidence of breast cancer and population LAN levels worldwide. This epidemiological evidence led the International Agency for Research on Cancer to classify shift work as a probable human carcinogen (Straif, et al. 2007). The molecular basis for effects of LAN on breast cancer are unknown, but inasmuch as the synthesis and secretion of melatonin from the pineal gland at night is very sensitive to suppression by LAN (Vanecek 1998), specifically only blue light in the wavelength range of 450 – 480  nm (Sanchez-Barcelo, et al. 2012), the general thinking {{has been that the}} reduced melatonin may be permissive for increased proliferation of breast epithelial cells and may thus {{play a role in the}} increased incidence of breast cancer (Sanchez-Barcelo, et al. 2012). Attention has also focused recently on the possibility that LAN exposure may affect circadian rythym through altering the expression of circadian genes and that this disruption of the circadian rhthym contributes to breast cancer development (Gery and Koeffler 2010; Savvidis and Koutsilieris 2012; Stevens 2009 a, b). The body’s circadian rythym is normally regulated by the expression of circadian genes in a master pacemaker in the suprachiasmatic nucleus of the hypothalamus that signals to oscillators in peripheral tissues (Savvidis and Koutsilieris 2012). As shown in this paper (Table  1), as well as by others (Fu, et al. 2011; Hoffman et al. 2010 a,b), circadian genes are expressed directly in breast cancer epithelial cells as well. Considerable evidence shows that expression of circadian genes are directly under the regulation of cGMP (Golombek, et al. 2004; Oster, et <b>al.</b> <b>et</b> al. 2003; Plano, et <b>al.</b> <b>et</b> al. 2012); thus, regulation of PDE 6 in breast cancer cells by light or by Wnt 5 a signaling through Frizzled- 2 and transducin, all of which we find expressed in breast cancer cells, could directly regulate the expression of circadian genes in these cells through alterations in cGMP levels. Although we find no evidence of rhodopsin in breast cancer cells to act as a light sensor, we do find high epression of CRY 2 in these cells, and CRY 2 can also act as a light sensor, absorbing light in its associated FAD molecule, intriguingly also specifically in the blue wavelength region of 450 – 480  nm (Hoang, et al. 2008), which may contribute to the activation of PDE 6 in these cells, and the alteration in cGMP levels, leading to dysregulation of circadian genes, alterations in circadian rythyms, and the inducement or perpetuation of the growth of breast cancer cells. It is also noteworthy that increased cGMP levels have been shown to inhibit proliferation and induce apoptosis in breast cancer cell lines (Saravani, et al. 2012; Tinsley, et <b>al.</b> <b>et</b> al. 2011) and it is thus possible that breast cancer cells have evolved to express PDE 6 as a means to protect themselves against cGMP-mediated apoptosis to ensure their continued growth. While there is still much to be done to decipher the true function(s) for the expression of the light-activated PDE 6 in breast cancer cells, this study nevertheless documents the expression of PDE 6 in these cells, thereby uncovering a potential novel means by which exposure to LAN may result in breast cancer growth and development.|$|E
30|$|First, {{the breakup}} of {{extended}} families into nuclear ones {{was caused by the}} dispersal of the original extended families and the separate placement of nuclear families at different locations in Israel, due to the availability of small apartments not suited to a large number of residents. In Ethiopia, the extended family aided and supported the couples. The breakup of this large social unit resulted in the loss of control, regulation and aid mechanisms for men and women alike. The forced transformation of these couples into unsupported nuclear families caused a lot of problems, e.g. women lost their family's support and/or could not run away from spousal violence, to seek refuge in their original families (Kacen, 2006; Sullivan, et <b>al.</b> <b>et</b> al. 2005; Sela-Shayovitz, 2010; Gal, 2003; Kacen and Keidar, 2006; Azezehu-Admasu, 2011; Tavaje, 2011).|$|E
40|$|International audienceWe are {{interested}} in Fully Packed Loops in a triangle (TFPLs), as introduced by Caselli at al. and studied by Thapper. We show that for Fully Packed Loops with a fixed link pattern (refined FPL), there exist linear recurrence relations with coefficients computed from TFPL configurations. We then give constraints and enumeration results for certain classes of TFPL configurations. For special boundary conditions, we show that TFPLs are counted by the famous Littlewood Richardson coefficients. Nous nous intéressons aux configurations de "Fully Packed Loops'' dans un triangle (TFPL), introduites par Caselli et <b>al.</b> <b>et</b> étudiées par Thapper. Nous montrons que pour les Fully Packed Loops avec un couplage donné, il existe des relations de récurrence linéaires dont les coefficients sont calculés à partir de certains TFPLs. Nous donnons ensuite des contraintes et des résultats énumératifs pour certaines familles de TFPLs. Pour certaines conditions au bord, nous montrons que le nombre de TFPL est donné par les coefficients de Littlewood Richardson...|$|E
30|$|The culture {{isolated}} had {{efficiency of}} accumulating on the sheets. Similar biodegradation assay {{has been documented}} by Satlewal <b>et</b> <b>al.</b> Sah <b>et</b> <b>al.,</b> Kapri <b>et</b> <b>al.</b> 2010 a, Kapri <b>et</b> <b>al.</b> 2010 b, Negi <b>et</b> <b>al.,</b> Soni <b>et</b> <b>al.</b> (Negi <b>et</b> <b>al.</b> 2009; Negi <b>et</b> <b>al.</b> 2011; Sah <b>et</b> <b>al.</b> 2010 a; Satlewal <b>et</b> <b>al.</b> 2008; Soni <b>et</b> <b>al.</b> 2009; Soni <b>et</b> <b>al.</b> 2008).|$|R
30|$|To sputter calcium orthophosphates, {{several types}} of the {{physical}} vapor deposition techniques are used, such as ion beam (Stevenson <b>et</b> <b>al.</b> 1989; Barthell <b>et</b> <b>al.</b> 1989; Ong <b>et</b> <b>al.</b> 1991, 1992, 1994; Yoshinari <b>et</b> <b>al.</b> 1994; Cui <b>et</b> <b>al.</b> 1997; Kim <b>et</b> <b>al.</b> 1998; Luo <b>et</b> <b>al.</b> 1999; Choi <b>et</b> <b>al.</b> 2000; Wang <b>et</b> <b>al.</b> 2001; Hamdi and Ide-Ektessabi 2003; Lee <b>et</b> <b>al.</b> 2003; Fujihara <b>et</b> <b>al.</b> 2004; Lee <b>et</b> <b>al.</b> 2005 b; Rabiei <b>et</b> <b>al.</b> 2006; Lee <b>et</b> <b>al.</b> 2007 a; Blalock <b>et</b> <b>al.</b> 2007), radio-frequency (RF) magnetron (Cooley <b>et</b> <b>al.</b> 1992; Yamashita <b>et</b> <b>al.</b> 1994; Jansen <b>et</b> <b>al.</b> 1993; Wolke <b>et</b> <b>al.</b> 1994; van Dijk <b>et</b> <b>al.</b> 1995, 1996; Wolke <b>et</b> <b>al.</b> 1998, 2003; Nelea <b>et</b> <b>al.</b> 2003, 2004; Feddes <b>et</b> <b>al.</b> 2003 a, 2003 b; Ding 2003; Yamaguchi <b>et</b> <b>al.</b> 2006; Wan <b>et</b> <b>al.</b> 2007; Ozeki <b>et</b> <b>al.</b> 2007; Ueda <b>et</b> <b>al.</b> 2007; Snyders <b>et</b> <b>al.</b> 2008; Ievlev <b>et</b> <b>al.</b> 2008; Toque <b>et</b> <b>al.</b> 2009), pulsed laser (Nelea <b>et</b> <b>al.</b> 2000, 2002, 2004; Cotell <b>et</b> <b>al.</b> 1992, Cotell 1993; Torrisi and Setola 1993; Cotell 1993; Singh <b>et</b> <b>al.</b> 1994; Wang <b>et</b> <b>al.</b> 1997; Hontsu <b>et</b> <b>al.</b> 1997; Fernández-Pradas <b>et</b> <b>al.</b> 1998, 1999, 2001; Mayor <b>et</b> <b>al.</b> 1998; Arias <b>et</b> <b>al.</b> 1998; Craciun <b>et</b> <b>al.</b> 1999; Fernandez-Pradas <b>et</b> <b>al.</b> 1999; Zeng <b>et</b> <b>al.</b> 2000; Cleries <b>et</b> <b>al.</b> 2000 a; Nelea <b>et</b> <b>al.</b> 2000; Zeng and Lacefield 2000; Fernandez-Pradas <b>et</b> <b>al.</b> 2001; Nelea <b>et</b> <b>al.</b> 2002; Socol <b>et</b> <b>al.</b> 2004; Kim <b>et</b> <b>al.</b> 2005 a; Bigi <b>et</b> <b>al.</b> 2005 b; Koch <b>et</b> <b>al.</b> 2007; Kim <b>et</b> <b>al.</b> 2007 a; Paital and Dahotre 2008; Paital <b>et</b> <b>al.</b> 2009; Dinda <b>et</b> <b>al.</b> 2009; Tri and Chua 2009; Sygnatowicz and Tiwari 2009), diode, direct current and reactive sputtering or deposition (Massaro <b>et</b> <b>al.</b> 2001). The physical and aggregate states of the calcium orthophosphate source might influence the deposition kinetics. For example, the deposition rate of HA {{was found to be}} much higher in a solid plate target than in a powder lump target, owing to the difference of apparent density approximately 75 % and approximately 18 %, respectively (Wan <b>et</b> <b>al.</b> 2007).|$|R
30|$|Carbon- 11 labeled L-methionine (11 C–MET) is a {{promising}} tracer for imaging brain tumors with {{positron emission tomography}} (PET) (Watanabe <b>et</b> <b>al.</b> 2016; Maffione <b>et</b> <b>al.</b> 2009; Glaudemans <b>et</b> <b>al.</b> 2013). Its synthesis has been previously optimized by 11 C–methylation of L-homocysteine in solution or on a C- 18 Sep-Pak cartridge with or without HPLC purification (Pascali <b>et</b> <b>al.</b> 1999; Tang <b>et</b> <b>al.</b> 2004; Lodia <b>et</b> <b>al.</b> 2007; Lodi <b>et</b> <b>al.</b> 2008; Boschi <b>et</b> <b>al.</b> 2009; Cheung <b>et</b> <b>al.</b> 2009; Quincoces <b>et</b> <b>al.</b> 2010; Pascali <b>et</b> <b>al.</b> 2011; Bogni <b>et</b> <b>al.</b> 2003; Nagren <b>et</b> <b>al.</b> 1998; Oh <b>et</b> <b>al.</b> 1998; Fukumura <b>et</b> <b>al.</b> 2004). While most groups reported >[*] 97 % radiochemical purity of 11 C–MET {{at the end of}} synthesis (EOS) even without HPLC purification, the stability of 11 C–MET in the final formulation solution has not been well documented in literature (Pascali <b>et</b> <b>al.</b> 1999; Tang <b>et</b> <b>al.</b> 2004; Lodia <b>et</b> <b>al.</b> 2007; Lodi <b>et</b> <b>al.</b> 2008; Boschi <b>et</b> <b>al.</b> 2009; Cheung <b>et</b> <b>al.</b> 2009; Quincoces <b>et</b> <b>al.</b> 2010; Pascali <b>et</b> <b>al.</b> 2011; Bogni <b>et</b> <b>al.</b> 2003; Nagren <b>et</b> <b>al.</b> 1998; Oh <b>et</b> <b>al.</b> 1998).|$|R
